Yongping You
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yongping You has a total of 583 co-authors. Here are the top co-authors by number of shared publications:
- Junxia Zhang
Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
104 shared publications - Xiuxing Wang
National Health Commission Key Laboratory of Antibody Techniques, Department of Cell Biology, Jiangsu Provincial Key Laboratory of Human Functional Genomics, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, China
100 shared publications - Qianghu Wang
Institute for Brain Tumours, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China
99 shared publications - Xu Qian
Department of Nutrition and Food Hygiene, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China
80 shared publications - Zhumei Shi
Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Avenue, Nanjing, 210029, China; Institute for Brain Tumors, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, 101 Longmian Avenue, Jiangning District, Nanjing, 211166, China
60 shared publications - Chenfei Lu
National Health Commission Key Laboratory of Antibody Techniques, Department of Cell Biology, Jiangsu Provincial Key Laboratory of Human Functional Genomics, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, Jiangsu, China
57 shared publications
Latest Publications
- Open Access
- 30 June 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1864031
Brusatol suppresses meningioma progression via targeting HMGCR to restrict the cholesterol biosynthesis and inhibit PI3K/AKT signaling pathway
Background: 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), a key enzyme in cholesterol metabolism, remains underexplored in meningioma. Additionally, the therapeutic potential of Brusatol (Bru), a triterpene lactone compound with anticancer properties, has yet to be systematically evaluated. This research investigates Bru’s efficacy in meningioma treatment and HMGCR-related mechanisms. Methods: IC 50 was determined using CCK-8 assay. Proliferation, apoptosis, migration, and invasion were assessed through colony formation, EdU, Annexin V/PI staining, Scratch, and Transwell assays, respectively. Cholesterol levels were measured with an assay kit and Filipin III probes. Key pathways and potential meningioma-specific marker were identified via multi-omics with GO/KEGG analyses and bioinformatic analyses. Protein expression was detected via Western blot analysis, and a mouse model of meningioma was employed to evaluate the efficacy of Bru. Results: Bru inhibited the proliferation, migration, and invasion of meningioma cells, induced apoptosis, and reduced cholesterol accumulation. Proteomic, transcriptomic, and bioinformatic analyses, along with molecular docking, revealed that Bru targeted HMGCR to restrict cholesterol biosynthesis and inhibit the PI3K/AKT signalling pathway. These findings were validated through a series of experiments, including surface plasmon resonance assay, HMGCR knockdown and overexpression, and rescue experiments where HMGCR knockdown or Bru treatment was reversed with an Akt activator SC79. In vivo experiments indicated that Bru effectively suppresses tumour progression, with no significant toxicity observed under the current experimental conditions. Conclusion: These findings demonstrate that Brusatol suppresses meningioma progression by inhibiting of HMGCR and the PI3K/AKT signaling pathway.
- 30 June 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1864031
Open AccessBrusatol suppresses meningioma progression via targeting HMGCR to restrict the cholesterol biosynthesis and inhibit PI3K/AKT signaling pathway
Background: 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), a key enzyme in cholesterol metabolism, remains underexplored in meningioma. Additionally, the therapeutic potential of Brusatol (Bru), a triterpene lactone compound with anticancer properties, has yet to be systematically evaluated. This research investigates Bru’s efficacy in meningioma treatment and HMGCR-related mechanisms. Methods: IC 50 was determined using CCK-8 assay. Proliferation, apoptosis, migration, and invasion were assessed through colony formation, EdU, Annexin V/PI staining, Scratch, and Transwell assays, respectively. Cholesterol levels were measured with an assay kit and Filipin III probes. Key pathways and potential meningioma-specific marker were identified via multi-omics with GO/KEGG analyses and bioinformatic analyses. Protein expression was detected via Western blot analysis, and a mouse model of meningioma was employed to evaluate the efficacy of Bru. Results: Bru inhibited the proliferation, migration, and invasion of meningioma cells, induced apoptosis, and reduced cholesterol accumulation. Proteomic, transcriptomic, and bioinformatic analyses, along with molecular docking, revealed that Bru targeted HMGCR to restrict cholesterol biosynthesis and inhibit the PI3K/AKT signalling pathway. These findings were validated through a series of experiments, including surface plasmon resonance assay, HMGCR knockdown and overexpression, and rescue experiments where HMGCR knockdown or Bru treatment was reversed with an Akt activator SC79. In vivo experiments indicated that Bru effectively suppresses tumour progression, with no significant toxicity observed under the current experimental conditions. Conclusion: These findings demonstrate that Brusatol suppresses meningioma progression by inhibiting of HMGCR and the PI3K/AKT signaling pathway.
- 15 June 2026
- Published by Elsevier in Cancer Letters
- Vol. 656, 218680
KRT18 promotes the high-grade meningioma proliferation by interacting with LDHA to activate glycolysis and the PI3K/AKT signaling pathway
- 15 June 2026
- Published by Elsevier in Cancer Letters
- Vol. 656, 218680
KRT18 promotes the high-grade meningioma proliferation by interacting with LDHA to activate glycolysis and the PI3K/AKT signaling pathway
- 15 April 2026
- Published by Elsevier in Cancer Letters
- Vol. 650, 218517
PGK1/PHGDH axis drives radioresistance in glioblastoma stem cells
- 15 April 2026
- Published by Elsevier in Cancer Letters
- Vol. 650, 218517
PGK1/PHGDH axis drives radioresistance in glioblastoma stem cells
- Open Access
- 23 February 2026
- Published by Elsevier in Cancer Letters
- Vol. 645, 218360
Clinical practice guidelines for the diagnosis and treatment of diffuse glioma-related epilepsy: 2025 update
- 23 February 2026
- Published by Elsevier in Cancer Letters
- Vol. 645, 218360
Open AccessClinical practice guidelines for the diagnosis and treatment of diffuse glioma-related epilepsy: 2025 update
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Dual Role of CXCL8 in Maintaining the Mesenchymal State of Glioblastoma Stem Cells and M2-Like Tumor-Associated Macrophages
Supplementary Figure S1-S7, and Supplementary table S1
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Dual Role of CXCL8 in Maintaining the Mesenchymal State of Glioblastoma Stem Cells and M2-Like Tumor-Associated Macrophages
Supplementary Figure S1-S7, and Supplementary table S1
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Dual Role of CXCL8 in Maintaining the Mesenchymal State of Glioblastoma Stem Cells and M2-Like Tumor-Associated Macrophages
Purpose:The dynamic interplay between glioblastoma stem cells (GSC) and tumor-associated macrophages (TAM) sculpts the tumor immune microenvironment (TIME) and promotes malignant progression of glioblastoma (GBM). However, the mechanisms underlying this interaction are still incompletely understood. Here, we investigate the role of CXCL8 in the maintenance of the mesenchymal state of GSC populations and reprogramming the TIME to an immunosuppressive state.Experimental Design:We performed an integrative multi-omics analyses of RNA sequencing, GBM mRNA expression datasets, immune signatures, and epigenetic profiling to define the specific genes expressed in the mesenchymal GSC subsets. We then used patient-derived GSCs and a xenograft murine model to investigate the mechanisms of tumor-intrinsic and extrinsic factor to maintain the mesenchymal state of GSCs and induce TAM polarization.Results:We identified that CXCL8 was preferentially expressed and secreted by mesenchymal GSCs and activated PI3K/AKT and NF-κB signaling to maintain GSC proliferation, survival, and self-renewal through a cell-intrinsic mechanism. CXCL8 induced signaling through a CXCR2–JAK2/STAT3 axis in TAMs, which supported an M2-like TAM phenotype through a paracrine, cell-extrinsic pathway. Genetic- and small molecule–based inhibition of these dual complementary signaling cascades in GSCs and TAMs suppressed GBM tumor growth and prolonged survival of orthotopic xenograft-bearing mice.Conclusions:CXCL8 plays critical roles in maintaining the mesenchymal state of GSCs and M2-like TAM polarization in GBM, highlighting an interplay between cell-autonomous and cell-extrinsic mechanisms. Targeting CXCL8 and its downstream effectors may effectively improve GBM treatment.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Dual Role of CXCL8 in Maintaining the Mesenchymal State of Glioblastoma Stem Cells and M2-Like Tumor-Associated Macrophages
Purpose:The dynamic interplay between glioblastoma stem cells (GSC) and tumor-associated macrophages (TAM) sculpts the tumor immune microenvironment (TIME) and promotes malignant progression of glioblastoma (GBM). However, the mechanisms underlying this interaction are still incompletely understood. Here, we investigate the role of CXCL8 in the maintenance of the mesenchymal state of GSC populations and reprogramming the TIME to an immunosuppressive state.Experimental Design:We performed an integrative multi-omics analyses of RNA sequencing, GBM mRNA expression datasets, immune signatures, and epigenetic profiling to define the specific genes expressed in the mesenchymal GSC subsets. We then used patient-derived GSCs and a xenograft murine model to investigate the mechanisms of tumor-intrinsic and extrinsic factor to maintain the mesenchymal state of GSCs and induce TAM polarization.Results:We identified that CXCL8 was preferentially expressed and secreted by mesenchymal GSCs and activated PI3K/AKT and NF-κB signaling to maintain GSC proliferation, survival, and self-renewal through a cell-intrinsic mechanism. CXCL8 induced signaling through a CXCR2–JAK2/STAT3 axis in TAMs, which supported an M2-like TAM phenotype through a paracrine, cell-extrinsic pathway. Genetic- and small molecule–based inhibition of these dual complementary signaling cascades in GSCs and TAMs suppressed GBM tumor growth and prolonged survival of orthotopic xenograft-bearing mice.Conclusions:CXCL8 plays critical roles in maintaining the mesenchymal state of GSCs and M2-like TAM polarization in GBM, highlighting an interplay between cell-autonomous and cell-extrinsic mechanisms. Targeting CXCL8 and its downstream effectors may effectively improve GBM treatment.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
Information of TAMs harboring tumor-derived mutations
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
Information of TAMs harboring tumor-derived mutations
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
Table S8. IHC scores of 95 GBM samples
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
Table S8. IHC scores of 95 GBM samples
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
Table S6. Cox regression analysis in CGGA GBM patients
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
Table S6. Cox regression analysis in CGGA GBM patients
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
Table S2. Logistic regression analysis from GLASS database
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
Table S2. Logistic regression analysis from GLASS database